title: [The clinical significance of MDR-1 gene expression in the hemopoietic cells of patients with acute leukemias in different phases of the disease].
abstract: OBJECTIVE
  Analysis of cytostatic therapy effects on expression of gene MDR-1 in hemopoietic cells of patients with acute leukemia (AL) in complete clinicohematological remission (CCHR).
  
  
  METHODS
  The study included 48 AL patients. 27 of them were untreated, 25 were resistant to or had recurrent AL. 4 patients were followed up. Bone marrow mononuclear fraction was investigated. Expression of MDR-1 gene in the cells was evaluated at hybridization.
  
  
  RESULTS
  High expression of MDR-1 gene occurred in leukemic blast cells either upon achievement of CCHR or at least 6 months after its onset. When using schemes of chemotherapy containing two potential inductors of gene MDR-1, expression of this gene was registered significantly more frequently than in using schemes based on one inducing drug (p < 0.05). Frequency of occurrence of enhanced expression of gene MDR-1 in leukemic blasts significantly correlated with frequency of CCHR (p < 0.05). Correlation between occurrence of the gene's expression in normal hemopoietic cells in CCHR and occurrence of early AL recurrences was not found.
  
  
  CONCLUSIONS
  The findings may facilitate design of new AL treatment programs.
authors.forename: T V
authors.initials: TV
authors.lastname: Bykova
authors.forename: A A
authors.initials: AA
authors.lastname: Sominskaia
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Zaritskiĭ
authors.forename: I Iu
authors.initials: IIu
authors.lastname: Stiuf
authors.forename: B V
authors.initials: BV
authors.lastname: Medvedeva
authors.forename: N A
authors.initials: NA
authors.lastname: Anikina
authors.forename: B V
authors.initials: BV
authors.lastname: Afanas'ev
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000166:cytology* / Q000187:drug effects; D018432:Drug Resistance, Multiple / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects / Q000235:genetics*; D019450:Genes, MDR / Q000187:drug effects / Q000235:genetics*; D006410:Hematopoiesis / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D017403:In Situ Hybridization; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics*; D012074:Remission Induction; D013997:Time Factors